Clinical Trials Logo
NCT number NCT01900093
Study type Interventional
Source Icahn School of Medicine at Mount Sinai
Contact Colleen Farrell, MA, CCRC
Phone 212-241-3048
Email colleen.farrell@mssm.edu
Status Recruiting
Phase N/A
Start date July 2013
Completion date November 2016
View Details

Clinical Trial Summary

Although ACTHAR gel is approved for the treatment of acute relapses, it is currently not widely used. Thus, we propose to conduct a small open-label proof-of-concept trial to evaluate the response to ACTHAR gel therapy in patients who have failed to make a satisfactory recovery after treatment with high dose IVMP. Documentation of the clinical course as well as any adverse events related to IVMP use will be made. The investigators propose to study the potential benefit of a 14-day course (the dose historically used since the landmark clinical trial of Rose et al1) of subcutaneous ACTHAR gel in 10 patients who have demonstrated inadequate improvement after a course of IVMP, 1000 mg daily, for 5 treatments (over a maximum of 8 days). These would be patients for whom PLEX would be considered as a treatment possibility. The primary outcome measure will be improvement in the targeted neurological deficit, as measured on the appropriate functional system score (FSS) of the EDSS.


Clinical Trial Description

This is an open-label, small, proof-of-concept study examining the safety, tolerability, and extent of recovery of a two-week course of subcutaneous Acthar Gel therapy in patients with MS relapse who have failed to make a satisfactory recovery after treatment with high dose methylprednisolone. Eligible patients will be given 80 units of Acthar for 14 days. Patients will be evaluated at baseline, at 1 week of Acthar treatment, at completion of Acthar treatment, and 1 week after completion of treatment. For those who do not undergo plasmapheresis an additional evaluation will be conducted 2 weeks after completion of treatment. Monitoring will include blood pressure determination and blood sugar determination.


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Clinical Trial Details
See also
Status Clinical Trial Phase
 Not yet recruiting NCT02740361 - Online Program to Reduce Depression in MS N/A
 Not yet recruiting NCT02810314 - Default Mode Network in Multiple Sclerosis N/A
 Recruiting NCT02283671 - Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Phase 1
 Recruiting NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon Phase 4
 Recruiting NCT02571335 - Impacts of Different Training Modes (Intense Versus Ordinary) on the Immune System and Memory Functions in pwMS N/A
 Recruiting NCT02544373 - CPAP to Treat Cognitive Dysfunction in MS N/A
 Not yet recruiting NCT02522962 - Innovative Physiotherapy and Coordination of Care for People With MS: a RCT and a Qualitative Study N/A
 Not yet recruiting NCT01954823 - Use of an Electronic Diary by People With Multiple Sclerosis N/A
 Not yet recruiting NCT02524093 - The Impact of Positive Mental Training in Multiple Sclerosis Phase 2
 Recruiting NCT02263339 - Exercise & Brain Health in MS N/A
 Recruiting NCT02282878 - The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis N/A
 Recruiting NCT02777060 - Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures N/A
 Recruiting NCT02364505 - A Telemedicine Mindfulness-based Intervention for People With Multiple Sclerosis and Their Caregivers N/A
 Recruiting NCT02232061 - Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod Phase 4
 Recruiting NCT02836327 - Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders N/A
 Recruiting NCT02538094 - tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis N/A
 Recruiting NCT02408380 - Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720) N/A
 Recruiting NCT02307877 - Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate N/A
 Active, not recruiting NCT02290990 - Efficacy Study of "Imaginative Distention", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS N/A
 Completed NCT02301442 - Step it Up: An Exercise and Behaviour Change Programme for People With Multiple Sclerosis N/A